Picture loading failed.

Anti-VEGFA;ANGPT2 therapeutic antibody (Pre-made Faricimab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-204-1mg 1mg 3090
GMP-Bios-ab-204-10mg 10mg 21890
GMP-Bios-ab-204-100mg 100mg 148000
GMP-Bios-ab-204-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-VEGFA;ANGPT2 therapeutic antibody (Pre-made Faricimab biosimilar,Bispecific mAb)
INN Name Faricimab
TargetVEGFA;ANGPT2
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure1cz8:HL:YX;None
99% SI StructureNone;None
95-98% SI Structure1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC
Year Proposed2017
Year Recommended2018
CompaniesChugai Pharmaceutical;Roche
Conditions Approvedna
Conditions ActiveDiabetic macular oedema;Wet age-related macular degeneration;Retinal oedema
Conditions Discontinuedna
Development TechDual-Affinity Re-Targeting Technology